Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsDivislaboratories

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Buy Divis Labs, Berger Paints, Liberty Phosphate: Tulsian

      In CNBC-TV18's popular show Bull's Eye, SP Tulsian, sptulsian.com shares trading strategy of the day.

    • Bull's eye: Buy Berger Paints, Hindalco, Marico, Cipla

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • Buy Geometric, Divis Labs, says Sudarshan Sukhani

      Buy Geometric and Divis Laboratories, says Sudarshan Sukhani, s2analytics.com. Divis Lab correction now comes at Rs 1050 and that is a very strong support level. It is also some kind of a micro double bottom here, so it is a buying opportunity, he adds.

    • Short Federal & OBC, buy Geometric & Divis: Sukhani

      Short Federal bank & Orient bank, says Sudarshan Sukhani of s2analytics.com. He has been upbeat on the CNX-IT index and that has finally percolated to the middle level IT stocks. "For the next week I am looking to buy Geometric", he adds

    • Buy Divi's Lab, Idea, LIC Hsg Finance: Parag Doctor

      In CNBC-TV18's popular show Bull's Eye, Parag Doctor of Keynote Capital shares trading strategy of the day.

    • Bull's Eye: Buy Idea, NHPC, Kalpataru Power, LIC Housing

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • Buy Dr Reddy's; Divis Lab, Biocon good bets: IIFL Cap

      Concentrating on the pharma space, Bino Pathiparampil of IIFL Capital told CNBC-TV18 the success of Biocon‘s oral insulin product deal would be a positive for the company. He also has a buy on Dr Reddy‘s and believes it should give a 25 percent plus upside in the next one year.

    • See upside in Divis Lab, LIC Housing Finance: Sukhani

      Sudarshan Sukhani of s2analytics.com feels that there will be more upside in Divis Laboratories and LIC Housing Finance.

    • See upmove in Divis Lab, says Sudarshan Sukhani

      See upmove in Divis Laboratories, says Sudarshan Sukhani of s2analytics.com. It had a big rally from Rs 700 to almost Rs 1000 and then it corrected. That correction is now over. It is now standing exactly at the correction level and now making the right choices by moving up having a higher close as compared to the previous close.

    • See good upside in Dr Reddy's, Divis, Torrent Pharma: IIFL

      Bino Pathiparampil of IIFL is bullish on Dr. Reddy‘s, Divi‘s Laboratories and Torrent Pharma. These stocks have attractive valuations and strong growth prospects. "These three stocks have good upside even in this market," he told CNBC-TV18.

    • Nifty may not fall below 5350; selective on infra: Tulsian

      SP Tulsian, of sptulsian.com, says that he expect the Nifty to not fall below 5350 level. Bank Nifty has reached a level of 11400-11500. Bank Nifty can again fall to a low of 10200 as Bank Nifty is exhibiting the maximum activity.

    • Short Sterlite Industries, says Sudarshan Sukhani

      Short Sterlite Industries, says Sudarshan Sukhani of s2analytics.com.

    • Buy Divis Lab, Hexaware, Madras Cements: Ashish Kapur

      In CNBC-TV18's popular show Bull's Eye, Ashish Kapur of Investshoppe shares trading strategy of the day.

    • Bull's eye: Buy HDIL, Divis Labs, Hexaware, Yes Bank

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • Buy Sun TV, Divis Labs, Zee Entertainment: Kapur

      In CNBC-TV18's popular show Bull's Eye, Ashish Kapur of Investshoppe shares trading strategy of the day.

    • Bull's eye: Buy HPCL, Sun TV; short CESC, Adani Ports

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • Check out: Darashaw's stock picks and wealth creators

      Regan F Homavazir continues to remain bullish on HDFC Bank because the longer term picture is extremely positive. He also likes J&K Bank.

    • Drug makers in India to sustain 'premium' valuations: HSBC

      HSBC raises target prices for some Indian drug makers saying "robust" earnings will help sustain the "premium" valuations in the sector.

    • Divis Labs better than Sun Pharma for trader: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that long term investor can hold Sun Pharma. For a short-term trader Divis Lab is probably a better option than Sun Pharma.

    • Super Six stocks you can bet on August 6

      On CNBC-TV18's show Super Six, market gurus Manas Jaiswal, Technical Analyst, manasjaiswal.com, Rajesh Jain, EVP Retail Research, Religare Sec and Rakesh Gandhi, Sr Technical Analyst, LKP, place their bets on two stocks each, thus offering investors a variety of options to choose from.

    • Buy Divis Laboratories on dips: Sukhani

      Buy Divis Laboratories on dips, says Sudarshan Sukhani of s2analytics.com.

    • Buy Divis Labs, LIC Hsg Fin, GSPL: Parag Doctor

      In CNBC-TV18's popular show Bull's Eye, Parag Doctor, Keynote Capital shares trading strategy of the day.

    • Bull's Eye: Buy BPCL, Cox & Kings, GSPL, LIC Hsg Fin

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • Buy Divis Laboratories, says Sudarshan Sukhani

      Buy Divis Laboratories, says Sudarshan Sukhani of s2analytics.com.

    • Divis Laboratories looks attractive: Sukhani

      Divis Laboratories is looking attractive, says Sudarshan Sukhani of s2analytics.com.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347